Healthcare Finance Staff
Capital access holds stable after King v. Burwell decision upholding subsidized health insurance pr…
While the Supreme Court decision in King v. Burwell that cleared subsidized health insurance premiums under the Affordable Care Act removed a lot of uncertainty from hospital finance, little has changed when it comes to hospitals' access to debt. But that may change.
On Thursday, providers dealt with system issues, which will be followed by productivity issues and then payment issues, according to healthcare insiders.
Healthcare Finance spent the bulk of Thursday's rollout monitoring the buzz, speaking with experts and reporting on any issues that may have arrived. While the true effects of the change will be felt in the coming weeks when claims are processed, bills delivered and accounts receivable wane, we have a few observations to share.
Insurance companies will pay $362 million to the federal government's shared risk program beginning this November for 2014 participation, but will be short $2.5 billion in payments that they hoped to receive from the federal government, the Department of Health and Human Services announced on Thursday.
Healthcare IT News and sister site Healthcare Finance will be reporting on the changeover throughout the day, using the live blog below to highlight the latest news, real-time reactions and frequent updates from our cadre of volunteer ICD-10 correspondents.
A federal judge has partly sided with providers in ordering the Centers for Medicare & Medicaid to provide further justification for the 0.2 percent payment reduction in provider compensation that will kick in under the two-midnight rule, according to the September 21 ruling in U.S. District Court in Washington D.C.
With the current shift to value-based reimbursement, providers are facing noteworthy changes as healthcare consumers are under more financial pressure than ever before.
Mark T. Bertolini, chairman and CEO of Aetna in Hartford, Connecticut and Joseph R. Swedish, president and CEO of Anthem in Indianapolis, argued before a Senate Judiciary subcommittee on Antitrust, Competition Policy and Consumer Rights on Tuesday that local insurance plans would keep the industry competitive.
The National Committee for Quality Assurance has released its newest rankings for health plans in the United States based on clinical and satisfaction scores.
Earlier this week, Turing Pharmaceutical CEO Martin Shkreli drew sharp criticism after his privately held company boosted the price of AIDS treatment drug Daraprim from a reported $13.50 a tablet to $750.